nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—CYP3A4—Methylprednisolone—psoriatic arthritis	0.0539	0.161	CbGbCtD
Irbesartan—CYP2C8—Dexamethasone—psoriatic arthritis	0.0503	0.15	CbGbCtD
Irbesartan—CYP3A4—Triamcinolone—psoriatic arthritis	0.0409	0.122	CbGbCtD
Irbesartan—CYP2C9—Dexamethasone—psoriatic arthritis	0.0351	0.105	CbGbCtD
Irbesartan—CYP3A4—Betamethasone—psoriatic arthritis	0.0351	0.105	CbGbCtD
Irbesartan—CYP3A4—Prednisolone—psoriatic arthritis	0.0346	0.103	CbGbCtD
Irbesartan—CYP3A4—Prednisone—psoriatic arthritis	0.0327	0.0976	CbGbCtD
Irbesartan—CYP2D6—Dexamethasone—psoriatic arthritis	0.0321	0.0958	CbGbCtD
Irbesartan—CYP3A4—Dexamethasone—psoriatic arthritis	0.0204	0.0609	CbGbCtD
Irbesartan—AGTR1—ACE Inhibitor Pathway—ACE—psoriatic arthritis	0.00559	0.0715	CbGpPWpGaD
Irbesartan—Losartan—ACE—psoriatic arthritis	0.00447	1	CrCbGaD
Irbesartan—JUN—ATF-2 transcription factor network—IL23A—psoriatic arthritis	0.00366	0.0468	CbGpPWpGaD
Irbesartan—JUN—IL12 signaling mediated by STAT4—IL13—psoriatic arthritis	0.0032	0.0409	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—LTA—psoriatic arthritis	0.00252	0.0323	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.00241	0.0308	CbGpPWpGaD
Irbesartan—JUN—Regulation of Androgen receptor activity—REL—psoriatic arthritis	0.00222	0.0284	CbGpPWpGaD
Irbesartan—JUN—IL-1 signaling pathway—REL—psoriatic arthritis	0.00215	0.0276	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-C—psoriatic arthritis	0.00199	0.0254	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL13—psoriatic arthritis	0.00197	0.0253	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.00194	0.0249	CbGpPWpGaD
Irbesartan—JUN—Betamethasone—Methylprednisolone—psoriatic arthritis	0.00184	0.105	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Methylprednisolone—psoriatic arthritis	0.00184	0.105	CbGdCrCtD
Irbesartan—AGTR1—Allograft Rejection—IL17A—psoriatic arthritis	0.00182	0.0232	CbGpPWpGaD
Irbesartan—JUN—Betamethasone—Dexamethasone—psoriatic arthritis	0.00181	0.104	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Betamethasone—psoriatic arthritis	0.00181	0.104	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Triamcinolone—psoriatic arthritis	0.00177	0.101	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Triamcinolone—psoriatic arthritis	0.00177	0.101	CbGdCrCtD
Irbesartan—PTGS1—Overview of nanoparticle effects—CRP—psoriatic arthritis	0.00169	0.0217	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—IL12B—psoriatic arthritis	0.00169	0.0216	CbGpPWpGaD
Irbesartan—JUN—Dexamethasone—Prednisone—psoriatic arthritis	0.00168	0.0961	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisone—psoriatic arthritis	0.00168	0.0961	CbGdCrCtD
Irbesartan—JUN—Betamethasone—Prednisolone—psoriatic arthritis	0.00164	0.0938	CbGdCrCtD
Irbesartan—JUN—Dexamethasone—Prednisolone—psoriatic arthritis	0.00164	0.0938	CbGdCrCtD
Irbesartan—JUN—IL12 signaling mediated by STAT4—HLA-DRB1—psoriatic arthritis	0.00161	0.0206	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—REL—psoriatic arthritis	0.00145	0.0186	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TNFRSF1B—psoriatic arthritis	0.00145	0.0185	CbGpPWpGaD
Irbesartan—JUN—MAP kinase activation in TLR cascade—NOD2—psoriatic arthritis	0.00144	0.0184	CbGpPWpGaD
Irbesartan—JUN—Glucocorticoid receptor regulatory network—IL13—psoriatic arthritis	0.00143	0.0183	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—REL—psoriatic arthritis	0.00143	0.0183	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—REL—psoriatic arthritis	0.00137	0.0175	CbGpPWpGaD
Irbesartan—JUN—Apoptosis Modulation and Signaling—TNFRSF1B—psoriatic arthritis	0.00136	0.0174	CbGpPWpGaD
Irbesartan—JUN—Signaling mediated by p38-alpha and p38-beta—NOS2—psoriatic arthritis	0.00136	0.0174	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNFRSF1B—psoriatic arthritis	0.00135	0.0172	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—IL17A—psoriatic arthritis	0.00122	0.0156	CbGpPWpGaD
Irbesartan—JUN—IL6-mediated signaling events—CRP—psoriatic arthritis	0.00118	0.015	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-B—psoriatic arthritis	0.00117	0.015	CbGpPWpGaD
Irbesartan—JUN—TRAF6 Mediated Induction of proinflammatory cytokines—NOD2—psoriatic arthritis	0.00114	0.0146	CbGpPWpGaD
Irbesartan—JUN—MyD88 cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00103	0.0132	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—IL12B—psoriatic arthritis	0.00103	0.0132	CbGpPWpGaD
Irbesartan—JUN—TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation—NOD2—psoriatic arthritis	0.00102	0.013	CbGpPWpGaD
Irbesartan—JUN—MyD88 dependent cascade initiated on endosome—NOD2—psoriatic arthritis	0.001	0.0128	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—HLA-DRB1—psoriatic arthritis	0.000994	0.0127	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 9 (TLR9) Cascade—NOD2—psoriatic arthritis	0.000966	0.0124	CbGpPWpGaD
Irbesartan—JUN—MyD88:Mal cascade initiated on plasma membrane—NOD2—psoriatic arthritis	0.00095	0.0121	CbGpPWpGaD
Irbesartan—JUN—MyD88-independent cascade—NOD2—psoriatic arthritis	0.000911	0.0117	CbGpPWpGaD
Irbesartan—JUN—ATF-2 transcription factor network—NOS2—psoriatic arthritis	0.000893	0.0114	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL13—psoriatic arthritis	0.000856	0.0109	CbGpPWpGaD
Irbesartan—JUN—Activated TLR4 signalling—NOD2—psoriatic arthritis	0.00082	0.0105	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—NOS2—psoriatic arthritis	0.000817	0.0104	CbGpPWpGaD
Irbesartan—JUN—HIF-1-alpha transcription factor network—NOS2—psoriatic arthritis	0.000817	0.0104	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—IL12B—psoriatic arthritis	0.000803	0.0103	CbGpPWpGaD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—NOD2—psoriatic arthritis	0.000771	0.00986	CbGpPWpGaD
Irbesartan—PTGS1—Overview of nanoparticle effects—TNF—psoriatic arthritis	0.000766	0.0098	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—NOD2—psoriatic arthritis	0.000687	0.00878	CbGpPWpGaD
Irbesartan—AGTR1—Angiopoietin receptor Tie2-mediated signaling—TNF—psoriatic arthritis	0.000678	0.00867	CbGpPWpGaD
Irbesartan—UGT1A3—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000671	0.00858	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriatic arthritis	0.00061	0.0078	CbGpPWpGaD
Irbesartan—Angiopathy—Prednisone—psoriatic arthritis	0.000598	0.00106	CcSEcCtD
Irbesartan—Conjunctivitis—Methotrexate—psoriatic arthritis	0.000596	0.00106	CcSEcCtD
Irbesartan—Immune system disorder—Prednisone—psoriatic arthritis	0.000595	0.00105	CcSEcCtD
Irbesartan—Malaise—Dexamethasone—psoriatic arthritis	0.000594	0.00105	CcSEcCtD
Irbesartan—Malaise—Betamethasone—psoriatic arthritis	0.000594	0.00105	CcSEcCtD
Irbesartan—Anaphylactic shock—Triamcinolone—psoriatic arthritis	0.000592	0.00105	CcSEcCtD
Irbesartan—Oedema—Triamcinolone—psoriatic arthritis	0.000592	0.00105	CcSEcCtD
Irbesartan—Vertigo—Betamethasone—psoriatic arthritis	0.000592	0.00105	CcSEcCtD
Irbesartan—Vertigo—Dexamethasone—psoriatic arthritis	0.000592	0.00105	CcSEcCtD
Irbesartan—Anaphylactic shock—Methylprednisolone—psoriatic arthritis	0.000591	0.00105	CcSEcCtD
Irbesartan—JUN—Innate Immune System—MEFV—psoriatic arthritis	0.000591	0.00756	CbGpPWpGaD
Irbesartan—Syncope—Dexamethasone—psoriatic arthritis	0.000591	0.00105	CcSEcCtD
Irbesartan—Syncope—Betamethasone—psoriatic arthritis	0.000591	0.00105	CcSEcCtD
Irbesartan—Arrhythmia—Prednisone—psoriatic arthritis	0.000589	0.00104	CcSEcCtD
Irbesartan—Infection—Triamcinolone—psoriatic arthritis	0.000589	0.00104	CcSEcCtD
Irbesartan—Infection—Methylprednisolone—psoriatic arthritis	0.000587	0.00104	CcSEcCtD
Irbesartan—Shock—Triamcinolone—psoriatic arthritis	0.000583	0.00103	CcSEcCtD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—TNF—psoriatic arthritis	0.000582	0.00745	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—TNF—psoriatic arthritis	0.000582	0.00745	CbGpPWpGaD
Irbesartan—Shock—Methylprednisolone—psoriatic arthritis	0.000582	0.00103	CcSEcCtD
Irbesartan—Hepatobiliary disease—Methotrexate—psoriatic arthritis	0.00058	0.00103	CcSEcCtD
Irbesartan—Nervous system disorder—Methylprednisolone—psoriatic arthritis	0.00058	0.00103	CcSEcCtD
Irbesartan—Loss of consciousness—Betamethasone—psoriatic arthritis	0.000579	0.00102	CcSEcCtD
Irbesartan—Loss of consciousness—Dexamethasone—psoriatic arthritis	0.000579	0.00102	CcSEcCtD
Irbesartan—Epistaxis—Methotrexate—psoriatic arthritis	0.000579	0.00102	CcSEcCtD
Irbesartan—Paraesthesia—Prednisolone—psoriatic arthritis	0.000578	0.00102	CcSEcCtD
Irbesartan—Tachycardia—Triamcinolone—psoriatic arthritis	0.000578	0.00102	CcSEcCtD
Irbesartan—Tachycardia—Methylprednisolone—psoriatic arthritis	0.000577	0.00102	CcSEcCtD
Irbesartan—Skin disorder—Methylprednisolone—psoriatic arthritis	0.000574	0.00102	CcSEcCtD
Irbesartan—Erythema—Prednisone—psoriatic arthritis	0.000574	0.00102	CcSEcCtD
Irbesartan—Malnutrition—Prednisone—psoriatic arthritis	0.000574	0.00102	CcSEcCtD
Irbesartan—Hyperhidrosis—Triamcinolone—psoriatic arthritis	0.000573	0.00101	CcSEcCtD
Irbesartan—Agranulocytosis—Methotrexate—psoriatic arthritis	0.000572	0.00101	CcSEcCtD
Irbesartan—Hyperhidrosis—Methylprednisolone—psoriatic arthritis	0.000571	0.00101	CcSEcCtD
Irbesartan—Hypertension—Betamethasone—psoriatic arthritis	0.000569	0.00101	CcSEcCtD
Irbesartan—Hypertension—Dexamethasone—psoriatic arthritis	0.000569	0.00101	CcSEcCtD
Irbesartan—Myalgia—Dexamethasone—psoriatic arthritis	0.000561	0.000992	CcSEcCtD
Irbesartan—Myalgia—Betamethasone—psoriatic arthritis	0.000561	0.000992	CcSEcCtD
Irbesartan—Anxiety—Dexamethasone—psoriatic arthritis	0.000559	0.000989	CcSEcCtD
Irbesartan—Anxiety—Betamethasone—psoriatic arthritis	0.000559	0.000989	CcSEcCtD
Irbesartan—Discomfort—Betamethasone—psoriatic arthritis	0.000554	0.000981	CcSEcCtD
Irbesartan—Discomfort—Dexamethasone—psoriatic arthritis	0.000554	0.000981	CcSEcCtD
Irbesartan—Hypotension—Methylprednisolone—psoriatic arthritis	0.000552	0.000978	CcSEcCtD
Irbesartan—Pain—Prednisolone—psoriatic arthritis	0.000551	0.000975	CcSEcCtD
Irbesartan—Hepatitis—Methotrexate—psoriatic arthritis	0.000551	0.000975	CcSEcCtD
Irbesartan—Pharyngitis—Methotrexate—psoriatic arthritis	0.000546	0.000967	CcSEcCtD
Irbesartan—Urinary tract disorder—Methotrexate—psoriatic arthritis	0.000544	0.000962	CcSEcCtD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.000541	0.00692	CbGpPWpGaD
Irbesartan—Vision blurred—Prednisone—psoriatic arthritis	0.000541	0.000957	CcSEcCtD
Irbesartan—Urethral disorder—Methotrexate—psoriatic arthritis	0.00054	0.000955	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Triamcinolone—psoriatic arthritis	0.00054	0.000955	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methylprednisolone—psoriatic arthritis	0.000538	0.000953	CcSEcCtD
Irbesartan—Anaphylactic shock—Dexamethasone—psoriatic arthritis	0.000537	0.000951	CcSEcCtD
Irbesartan—Anaphylactic shock—Betamethasone—psoriatic arthritis	0.000537	0.000951	CcSEcCtD
Irbesartan—Oedema—Dexamethasone—psoriatic arthritis	0.000537	0.000951	CcSEcCtD
Irbesartan—Oedema—Betamethasone—psoriatic arthritis	0.000537	0.000951	CcSEcCtD
Irbesartan—Infection—Dexamethasone—psoriatic arthritis	0.000534	0.000945	CcSEcCtD
Irbesartan—Infection—Betamethasone—psoriatic arthritis	0.000534	0.000945	CcSEcCtD
Irbesartan—Ill-defined disorder—Prednisone—psoriatic arthritis	0.000532	0.000942	CcSEcCtD
Irbesartan—Paraesthesia—Triamcinolone—psoriatic arthritis	0.000532	0.000941	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisolone—psoriatic arthritis	0.000531	0.00094	CcSEcCtD
Irbesartan—Paraesthesia—Methylprednisolone—psoriatic arthritis	0.000531	0.000939	CcSEcCtD
Irbesartan—Visual impairment—Methotrexate—psoriatic arthritis	0.000531	0.000939	CcSEcCtD
Irbesartan—Anaemia—Prednisone—psoriatic arthritis	0.00053	0.000938	CcSEcCtD
Irbesartan—Shock—Betamethasone—psoriatic arthritis	0.000529	0.000936	CcSEcCtD
Irbesartan—Shock—Dexamethasone—psoriatic arthritis	0.000529	0.000936	CcSEcCtD
Irbesartan—Dyspnoea—Triamcinolone—psoriatic arthritis	0.000528	0.000935	CcSEcCtD
Irbesartan—Nervous system disorder—Dexamethasone—psoriatic arthritis	0.000527	0.000933	CcSEcCtD
Irbesartan—Nervous system disorder—Betamethasone—psoriatic arthritis	0.000527	0.000933	CcSEcCtD
Irbesartan—Agitation—Prednisone—psoriatic arthritis	0.000527	0.000933	CcSEcCtD
Irbesartan—Thrombocytopenia—Dexamethasone—psoriatic arthritis	0.000526	0.000931	CcSEcCtD
Irbesartan—Thrombocytopenia—Betamethasone—psoriatic arthritis	0.000526	0.000931	CcSEcCtD
Irbesartan—Tachycardia—Dexamethasone—psoriatic arthritis	0.000525	0.000928	CcSEcCtD
Irbesartan—Tachycardia—Betamethasone—psoriatic arthritis	0.000525	0.000928	CcSEcCtD
Irbesartan—Angioedema—Prednisone—psoriatic arthritis	0.000524	0.000928	CcSEcCtD
Irbesartan—Dyspepsia—Triamcinolone—psoriatic arthritis	0.000521	0.000923	CcSEcCtD
Irbesartan—Dyspepsia—Methylprednisolone—psoriatic arthritis	0.00052	0.000921	CcSEcCtD
Irbesartan—Hyperhidrosis—Dexamethasone—psoriatic arthritis	0.00052	0.00092	CcSEcCtD
Irbesartan—Hyperhidrosis—Betamethasone—psoriatic arthritis	0.00052	0.00092	CcSEcCtD
Irbesartan—Malaise—Prednisone—psoriatic arthritis	0.000517	0.000915	CcSEcCtD
Irbesartan—Vertigo—Prednisone—psoriatic arthritis	0.000515	0.000912	CcSEcCtD
Irbesartan—Syncope—Prednisone—psoriatic arthritis	0.000514	0.00091	CcSEcCtD
Irbesartan—Tinnitus—Methotrexate—psoriatic arthritis	0.000513	0.000909	CcSEcCtD
Irbesartan—Anorexia—Dexamethasone—psoriatic arthritis	0.000512	0.000907	CcSEcCtD
Irbesartan—Anorexia—Betamethasone—psoriatic arthritis	0.000512	0.000907	CcSEcCtD
Irbesartan—Urticaria—Prednisolone—psoriatic arthritis	0.000512	0.000906	CcSEcCtD
Irbesartan—Cardiac disorder—Methotrexate—psoriatic arthritis	0.000511	0.000904	CcSEcCtD
Irbesartan—Fatigue—Triamcinolone—psoriatic arthritis	0.000511	0.000904	CcSEcCtD
Irbesartan—Fatigue—Methylprednisolone—psoriatic arthritis	0.00051	0.000902	CcSEcCtD
Irbesartan—Pain—Triamcinolone—psoriatic arthritis	0.000507	0.000897	CcSEcCtD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—psoriatic arthritis	0.000506	0.00648	CbGpPWpGaD
Irbesartan—Loss of consciousness—Prednisone—psoriatic arthritis	0.000504	0.000892	CcSEcCtD
Irbesartan—Hypotension—Dexamethasone—psoriatic arthritis	0.000502	0.000889	CcSEcCtD
Irbesartan—Hypotension—Betamethasone—psoriatic arthritis	0.000502	0.000889	CcSEcCtD
Irbesartan—Angiopathy—Methotrexate—psoriatic arthritis	0.0005	0.000884	CcSEcCtD
Irbesartan—Immune system disorder—Methotrexate—psoriatic arthritis	0.000497	0.00088	CcSEcCtD
Irbesartan—PTGS1—Selenium Micronutrient Network—CRP—psoriatic arthritis	0.000497	0.00635	CbGpPWpGaD
Irbesartan—Mediastinal disorder—Methotrexate—psoriatic arthritis	0.000496	0.000878	CcSEcCtD
Irbesartan—Hypertension—Prednisone—psoriatic arthritis	0.000495	0.000876	CcSEcCtD
Irbesartan—Chills—Methotrexate—psoriatic arthritis	0.000494	0.000874	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Betamethasone—psoriatic arthritis	0.00049	0.000867	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Dexamethasone—psoriatic arthritis	0.00049	0.000867	CcSEcCtD
Irbesartan—Myalgia—Prednisone—psoriatic arthritis	0.000488	0.000864	CcSEcCtD
Irbesartan—Arthralgia—Prednisone—psoriatic arthritis	0.000488	0.000864	CcSEcCtD
Irbesartan—Feeling abnormal—Triamcinolone—psoriatic arthritis	0.000488	0.000864	CcSEcCtD
Irbesartan—Feeling abnormal—Methylprednisolone—psoriatic arthritis	0.000487	0.000862	CcSEcCtD
Irbesartan—Anxiety—Prednisone—psoriatic arthritis	0.000487	0.000861	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriatic arthritis	0.000485	0.000858	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methylprednisolone—psoriatic arthritis	0.000483	0.000855	CcSEcCtD
Irbesartan—Paraesthesia—Betamethasone—psoriatic arthritis	0.000483	0.000854	CcSEcCtD
Irbesartan—Paraesthesia—Dexamethasone—psoriatic arthritis	0.000483	0.000854	CcSEcCtD
Irbesartan—Discomfort—Prednisone—psoriatic arthritis	0.000482	0.000854	CcSEcCtD
Irbesartan—Erythema—Methotrexate—psoriatic arthritis	0.000479	0.000848	CcSEcCtD
Irbesartan—Malnutrition—Methotrexate—psoriatic arthritis	0.000479	0.000848	CcSEcCtD
Irbesartan—JUN—TGF-beta Receptor Signaling—TNF—psoriatic arthritis	0.000476	0.00609	CbGpPWpGaD
Irbesartan—Hypersensitivity—Prednisolone—psoriatic arthritis	0.000475	0.00084	CcSEcCtD
Irbesartan—Dyspepsia—Dexamethasone—psoriatic arthritis	0.000473	0.000837	CcSEcCtD
Irbesartan—Dyspepsia—Betamethasone—psoriatic arthritis	0.000473	0.000837	CcSEcCtD
Irbesartan—Urticaria—Triamcinolone—psoriatic arthritis	0.000471	0.000833	CcSEcCtD
Irbesartan—AGTR1—Allograft Rejection—TNF—psoriatic arthritis	0.00047	0.00601	CbGpPWpGaD
Irbesartan—Urticaria—Methylprednisolone—psoriatic arthritis	0.00047	0.000831	CcSEcCtD
Irbesartan—Dysgeusia—Methotrexate—psoriatic arthritis	0.000469	0.000831	CcSEcCtD
Irbesartan—Body temperature increased—Triamcinolone—psoriatic arthritis	0.000468	0.000829	CcSEcCtD
Irbesartan—Anaphylactic shock—Prednisone—psoriatic arthritis	0.000468	0.000829	CcSEcCtD
Irbesartan—Oedema—Prednisone—psoriatic arthritis	0.000468	0.000829	CcSEcCtD
Irbesartan—Abdominal pain—Methylprednisolone—psoriatic arthritis	0.000467	0.000827	CcSEcCtD
Irbesartan—Decreased appetite—Dexamethasone—psoriatic arthritis	0.000467	0.000827	CcSEcCtD
Irbesartan—Decreased appetite—Betamethasone—psoriatic arthritis	0.000467	0.000827	CcSEcCtD
Irbesartan—Infection—Prednisone—psoriatic arthritis	0.000465	0.000823	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Dexamethasone—psoriatic arthritis	0.000464	0.000821	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Betamethasone—psoriatic arthritis	0.000464	0.000821	CcSEcCtD
Irbesartan—Fatigue—Betamethasone—psoriatic arthritis	0.000463	0.00082	CcSEcCtD
Irbesartan—Fatigue—Dexamethasone—psoriatic arthritis	0.000463	0.00082	CcSEcCtD
Irbesartan—Shock—Prednisone—psoriatic arthritis	0.000461	0.000815	CcSEcCtD
Irbesartan—Pain—Dexamethasone—psoriatic arthritis	0.00046	0.000814	CcSEcCtD
Irbesartan—Pain—Betamethasone—psoriatic arthritis	0.00046	0.000814	CcSEcCtD
Irbesartan—Nervous system disorder—Prednisone—psoriatic arthritis	0.000459	0.000812	CcSEcCtD
Irbesartan—Tachycardia—Prednisone—psoriatic arthritis	0.000457	0.000809	CcSEcCtD
Irbesartan—Skin disorder—Prednisone—psoriatic arthritis	0.000455	0.000805	CcSEcCtD
Irbesartan—Hyperhidrosis—Prednisone—psoriatic arthritis	0.000453	0.000801	CcSEcCtD
Irbesartan—Vision blurred—Methotrexate—psoriatic arthritis	0.000452	0.0008	CcSEcCtD
Irbesartan—Anorexia—Prednisone—psoriatic arthritis	0.000446	0.00079	CcSEcCtD
Irbesartan—Ill-defined disorder—Methotrexate—psoriatic arthritis	0.000445	0.000787	CcSEcCtD
Irbesartan—Anaemia—Methotrexate—psoriatic arthritis	0.000443	0.000784	CcSEcCtD
Irbesartan—Feeling abnormal—Dexamethasone—psoriatic arthritis	0.000443	0.000784	CcSEcCtD
Irbesartan—Feeling abnormal—Betamethasone—psoriatic arthritis	0.000443	0.000784	CcSEcCtD
Irbesartan—Gastrointestinal pain—Betamethasone—psoriatic arthritis	0.00044	0.000778	CcSEcCtD
Irbesartan—Gastrointestinal pain—Dexamethasone—psoriatic arthritis	0.00044	0.000778	CcSEcCtD
Irbesartan—Hypersensitivity—Triamcinolone—psoriatic arthritis	0.000436	0.000772	CcSEcCtD
Irbesartan—Hypersensitivity—Methylprednisolone—psoriatic arthritis	0.000435	0.000771	CcSEcCtD
Irbesartan—Malaise—Methotrexate—psoriatic arthritis	0.000432	0.000765	CcSEcCtD
Irbesartan—Vertigo—Methotrexate—psoriatic arthritis	0.000431	0.000762	CcSEcCtD
Irbesartan—Leukopenia—Methotrexate—psoriatic arthritis	0.000429	0.000759	CcSEcCtD
Irbesartan—Urticaria—Betamethasone—psoriatic arthritis	0.000427	0.000756	CcSEcCtD
Irbesartan—Urticaria—Dexamethasone—psoriatic arthritis	0.000427	0.000756	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Prednisone—psoriatic arthritis	0.000426	0.000755	CcSEcCtD
Irbesartan—Dizziness—Prednisolone—psoriatic arthritis	0.000426	0.000754	CcSEcCtD
Irbesartan—Asthenia—Triamcinolone—psoriatic arthritis	0.000425	0.000752	CcSEcCtD
Irbesartan—Abdominal pain—Dexamethasone—psoriatic arthritis	0.000425	0.000752	CcSEcCtD
Irbesartan—Abdominal pain—Betamethasone—psoriatic arthritis	0.000425	0.000752	CcSEcCtD
Irbesartan—Body temperature increased—Dexamethasone—psoriatic arthritis	0.000425	0.000752	CcSEcCtD
Irbesartan—Body temperature increased—Betamethasone—psoriatic arthritis	0.000425	0.000752	CcSEcCtD
Irbesartan—Asthenia—Methylprednisolone—psoriatic arthritis	0.000424	0.000751	CcSEcCtD
Irbesartan—Paraesthesia—Prednisone—psoriatic arthritis	0.00042	0.000744	CcSEcCtD
Irbesartan—Pruritus—Triamcinolone—psoriatic arthritis	0.000419	0.000742	CcSEcCtD
Irbesartan—Cough—Methotrexate—psoriatic arthritis	0.000418	0.00074	CcSEcCtD
Irbesartan—Pruritus—Methylprednisolone—psoriatic arthritis	0.000418	0.00074	CcSEcCtD
Irbesartan—Dyspepsia—Prednisone—psoriatic arthritis	0.000412	0.000729	CcSEcCtD
Irbesartan—Arthralgia—Methotrexate—psoriatic arthritis	0.000408	0.000722	CcSEcCtD
Irbesartan—Chest pain—Methotrexate—psoriatic arthritis	0.000408	0.000722	CcSEcCtD
Irbesartan—Myalgia—Methotrexate—psoriatic arthritis	0.000408	0.000722	CcSEcCtD
Irbesartan—Decreased appetite—Prednisone—psoriatic arthritis	0.000407	0.00072	CcSEcCtD
Irbesartan—Rash—Prednisolone—psoriatic arthritis	0.000406	0.000719	CcSEcCtD
Irbesartan—Dermatitis—Prednisolone—psoriatic arthritis	0.000406	0.000718	CcSEcCtD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—TNF—psoriatic arthritis	0.000405	0.00519	CbGpPWpGaD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriatic arthritis	0.000405	0.000717	CcSEcCtD
Irbesartan—Diarrhoea—Methylprednisolone—psoriatic arthritis	0.000404	0.000716	CcSEcCtD
Irbesartan—Fatigue—Prednisone—psoriatic arthritis	0.000404	0.000714	CcSEcCtD
Irbesartan—Headache—Prednisolone—psoriatic arthritis	0.000404	0.000714	CcSEcCtD
Irbesartan—Discomfort—Methotrexate—psoriatic arthritis	0.000403	0.000714	CcSEcCtD
Irbesartan—Constipation—Prednisone—psoriatic arthritis	0.0004	0.000708	CcSEcCtD
Irbesartan—Dizziness—Triamcinolone—psoriatic arthritis	0.000392	0.000693	CcSEcCtD
Irbesartan—Anaphylactic shock—Methotrexate—psoriatic arthritis	0.000391	0.000692	CcSEcCtD
Irbesartan—Dizziness—Methylprednisolone—psoriatic arthritis	0.000391	0.000692	CcSEcCtD
Irbesartan—Infection—Methotrexate—psoriatic arthritis	0.000389	0.000688	CcSEcCtD
Irbesartan—Feeling abnormal—Prednisone—psoriatic arthritis	0.000386	0.000683	CcSEcCtD
Irbesartan—Asthenia—Betamethasone—psoriatic arthritis	0.000386	0.000683	CcSEcCtD
Irbesartan—Asthenia—Dexamethasone—psoriatic arthritis	0.000386	0.000683	CcSEcCtD
Irbesartan—Nervous system disorder—Methotrexate—psoriatic arthritis	0.000384	0.000679	CcSEcCtD
Irbesartan—Thrombocytopenia—Methotrexate—psoriatic arthritis	0.000383	0.000678	CcSEcCtD
Irbesartan—Gastrointestinal pain—Prednisone—psoriatic arthritis	0.000383	0.000677	CcSEcCtD
Irbesartan—Nausea—Prednisolone—psoriatic arthritis	0.000383	0.000677	CcSEcCtD
Irbesartan—Pruritus—Betamethasone—psoriatic arthritis	0.00038	0.000673	CcSEcCtD
Irbesartan—Pruritus—Dexamethasone—psoriatic arthritis	0.00038	0.000673	CcSEcCtD
Irbesartan—Skin disorder—Methotrexate—psoriatic arthritis	0.00038	0.000673	CcSEcCtD
Irbesartan—Hyperhidrosis—Methotrexate—psoriatic arthritis	0.000378	0.000669	CcSEcCtD
Irbesartan—Vomiting—Triamcinolone—psoriatic arthritis	0.000377	0.000667	CcSEcCtD
Irbesartan—Vomiting—Methylprednisolone—psoriatic arthritis	0.000376	0.000665	CcSEcCtD
Irbesartan—Rash—Triamcinolone—psoriatic arthritis	0.000374	0.000661	CcSEcCtD
Irbesartan—Dermatitis—Triamcinolone—psoriatic arthritis	0.000373	0.00066	CcSEcCtD
Irbesartan—Anorexia—Methotrexate—psoriatic arthritis	0.000373	0.00066	CcSEcCtD
Irbesartan—Rash—Methylprednisolone—psoriatic arthritis	0.000373	0.00066	CcSEcCtD
Irbesartan—Dermatitis—Methylprednisolone—psoriatic arthritis	0.000372	0.000659	CcSEcCtD
Irbesartan—Urticaria—Prednisone—psoriatic arthritis	0.000372	0.000658	CcSEcCtD
Irbesartan—Headache—Triamcinolone—psoriatic arthritis	0.000371	0.000657	CcSEcCtD
Irbesartan—Headache—Methylprednisolone—psoriatic arthritis	0.00037	0.000655	CcSEcCtD
Irbesartan—Abdominal pain—Prednisone—psoriatic arthritis	0.00037	0.000655	CcSEcCtD
Irbesartan—Body temperature increased—Prednisone—psoriatic arthritis	0.00037	0.000655	CcSEcCtD
Irbesartan—Diarrhoea—Dexamethasone—psoriatic arthritis	0.000368	0.000651	CcSEcCtD
Irbesartan—Diarrhoea—Betamethasone—psoriatic arthritis	0.000368	0.000651	CcSEcCtD
Irbesartan—Hypotension—Methotrexate—psoriatic arthritis	0.000366	0.000647	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Methotrexate—psoriatic arthritis	0.000356	0.000631	CcSEcCtD
Irbesartan—Dizziness—Betamethasone—psoriatic arthritis	0.000355	0.000629	CcSEcCtD
Irbesartan—Dizziness—Dexamethasone—psoriatic arthritis	0.000355	0.000629	CcSEcCtD
Irbesartan—Nausea—Triamcinolone—psoriatic arthritis	0.000352	0.000623	CcSEcCtD
Irbesartan—Paraesthesia—Methotrexate—psoriatic arthritis	0.000351	0.000622	CcSEcCtD
Irbesartan—Nausea—Methylprednisolone—psoriatic arthritis	0.000351	0.000621	CcSEcCtD
Irbesartan—Dyspnoea—Methotrexate—psoriatic arthritis	0.000349	0.000617	CcSEcCtD
Irbesartan—Somnolence—Methotrexate—psoriatic arthritis	0.000348	0.000616	CcSEcCtD
Irbesartan—Hypersensitivity—Prednisone—psoriatic arthritis	0.000345	0.00061	CcSEcCtD
Irbesartan—Dyspepsia—Methotrexate—psoriatic arthritis	0.000344	0.000609	CcSEcCtD
Irbesartan—JUN—Immune System—MEFV—psoriatic arthritis	0.000344	0.0044	CbGpPWpGaD
Irbesartan—Vomiting—Dexamethasone—psoriatic arthritis	0.000342	0.000605	CcSEcCtD
Irbesartan—Vomiting—Betamethasone—psoriatic arthritis	0.000342	0.000605	CcSEcCtD
Irbesartan—Decreased appetite—Methotrexate—psoriatic arthritis	0.00034	0.000602	CcSEcCtD
Irbesartan—Rash—Betamethasone—psoriatic arthritis	0.000339	0.0006	CcSEcCtD
Irbesartan—Rash—Dexamethasone—psoriatic arthritis	0.000339	0.0006	CcSEcCtD
Irbesartan—Dermatitis—Betamethasone—psoriatic arthritis	0.000339	0.000599	CcSEcCtD
Irbesartan—Dermatitis—Dexamethasone—psoriatic arthritis	0.000339	0.000599	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Methotrexate—psoriatic arthritis	0.000338	0.000598	CcSEcCtD
Irbesartan—Fatigue—Methotrexate—psoriatic arthritis	0.000337	0.000597	CcSEcCtD
Irbesartan—Headache—Betamethasone—psoriatic arthritis	0.000337	0.000596	CcSEcCtD
Irbesartan—Headache—Dexamethasone—psoriatic arthritis	0.000337	0.000596	CcSEcCtD
Irbesartan—Asthenia—Prednisone—psoriatic arthritis	0.000336	0.000594	CcSEcCtD
Irbesartan—JUN—Circadian rythm related genes—NOS2—psoriatic arthritis	0.000335	0.00429	CbGpPWpGaD
Irbesartan—Pain—Methotrexate—psoriatic arthritis	0.000335	0.000592	CcSEcCtD
Irbesartan—JUN—Apoptosis—TNF—psoriatic arthritis	0.000334	0.00428	CbGpPWpGaD
Irbesartan—Pruritus—Prednisone—psoriatic arthritis	0.000331	0.000586	CcSEcCtD
Irbesartan—Feeling abnormal—Methotrexate—psoriatic arthritis	0.000322	0.000571	CcSEcCtD
Irbesartan—Diarrhoea—Prednisone—psoriatic arthritis	0.00032	0.000567	CcSEcCtD
Irbesartan—Gastrointestinal pain—Methotrexate—psoriatic arthritis	0.00032	0.000566	CcSEcCtD
Irbesartan—Nausea—Betamethasone—psoriatic arthritis	0.000319	0.000565	CcSEcCtD
Irbesartan—Nausea—Dexamethasone—psoriatic arthritis	0.000319	0.000565	CcSEcCtD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNF—psoriatic arthritis	0.000311	0.00398	CbGpPWpGaD
Irbesartan—Urticaria—Methotrexate—psoriatic arthritis	0.000311	0.00055	CcSEcCtD
Irbesartan—Dizziness—Prednisone—psoriatic arthritis	0.00031	0.000548	CcSEcCtD
Irbesartan—Abdominal pain—Methotrexate—psoriatic arthritis	0.000309	0.000547	CcSEcCtD
Irbesartan—Body temperature increased—Methotrexate—psoriatic arthritis	0.000309	0.000547	CcSEcCtD
Irbesartan—JUN—Innate Immune System—HLA-C—psoriatic arthritis	0.000302	0.00387	CbGpPWpGaD
Irbesartan—Vomiting—Prednisone—psoriatic arthritis	0.000298	0.000527	CcSEcCtD
Irbesartan—Rash—Prednisone—psoriatic arthritis	0.000295	0.000522	CcSEcCtD
Irbesartan—Dermatitis—Prednisone—psoriatic arthritis	0.000295	0.000522	CcSEcCtD
Irbesartan—Headache—Prednisone—psoriatic arthritis	0.000293	0.000519	CcSEcCtD
Irbesartan—Hypersensitivity—Methotrexate—psoriatic arthritis	0.000288	0.00051	CcSEcCtD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—psoriatic arthritis	0.000286	0.00366	CbGpPWpGaD
Irbesartan—Asthenia—Methotrexate—psoriatic arthritis	0.000281	0.000497	CcSEcCtD
Irbesartan—Nausea—Prednisone—psoriatic arthritis	0.000278	0.000492	CcSEcCtD
Irbesartan—Pruritus—Methotrexate—psoriatic arthritis	0.000277	0.00049	CcSEcCtD
Irbesartan—Diarrhoea—Methotrexate—psoriatic arthritis	0.000268	0.000474	CcSEcCtD
Irbesartan—Dizziness—Methotrexate—psoriatic arthritis	0.000259	0.000458	CcSEcCtD
Irbesartan—Vomiting—Methotrexate—psoriatic arthritis	0.000249	0.00044	CcSEcCtD
Irbesartan—Rash—Methotrexate—psoriatic arthritis	0.000247	0.000437	CcSEcCtD
Irbesartan—Dermatitis—Methotrexate—psoriatic arthritis	0.000246	0.000436	CcSEcCtD
Irbesartan—Headache—Methotrexate—psoriatic arthritis	0.000245	0.000434	CcSEcCtD
Irbesartan—Nausea—Methotrexate—psoriatic arthritis	0.000232	0.000411	CcSEcCtD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—psoriatic arthritis	0.000225	0.00288	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—psoriatic arthritis	0.000223	0.00286	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—NOD2—psoriatic arthritis	0.000222	0.00284	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—psoriatic arthritis	0.000204	0.00261	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—psoriatic arthritis	0.000192	0.00246	CbGpPWpGaD
Irbesartan—JUN—Immune System—REL—psoriatic arthritis	0.000191	0.00245	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—HLA-B—psoriatic arthritis	0.000179	0.00229	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-C—psoriatic arthritis	0.000176	0.00225	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—psoriatic arthritis	0.000173	0.00222	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriatic arthritis	0.00017	0.00217	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriatic arthritis	0.00017	0.00217	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CRP—psoriatic arthritis	0.000158	0.00202	CbGpPWpGaD
Irbesartan—JUN—Immune System—NOD2—psoriatic arthritis	0.00013	0.00166	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-B—psoriatic arthritis	0.000104	0.00133	CbGpPWpGaD
Irbesartan—JUN—Immune System—CRP—psoriatic arthritis	9.21e-05	0.00118	CbGpPWpGaD
Irbesartan—JUN—Immune System—HLA-DRB1—psoriatic arthritis	8.82e-05	0.00113	CbGpPWpGaD
